Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614233 · ClinicalTrials.gov registry record · Phase 4
Targeting the Gut-brain Axis to Facilitate Weight Loss in High Fat Diet Consumers
A Phase 4 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT04614233 is a Phase 4 study that was terminated before completion, run by Yale University. The registered enrollment target is 64 participants.
The verdict
NCT04614233, a Phase 4 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary objective is to test if fat intake moderates the ability of oleoylethanolamide (OEA) to improve weight loss maintenance after the LEARN® weight loss program.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT RiduZone (90% OEA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614233
The ClinicalTrials.gov registry entry for NCT04614233 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04614233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04614233 about?
NCT04614233 is a clinical study titled "Targeting the Gut-brain Axis to Facilitate Weight Loss in High Fat Diet Consumers". The primary objective is to test if fat intake moderates the ability of oleoylethanolamide (OEA) to improve weight loss maintenance after the LEARN® weight loss program.
What is the current status of trial NCT04614233?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2021-04-06. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT04614233?
The interventions under investigation include: Placebo (DRUG), RiduZone (90% OEA) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04614233?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.